MarketCapExport financials
Ultragenyx Pharmaceutical (RARE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Ultragenyx Pharmaceutical Balance Sheet 2025-2011 | RARE
Brief overview of Ultragenyx Pharmaceutical 's balance sheet structure
Balance sheet changes are traced across five available annual reports between 2021 and 2025.
The asset base was stable: the change from $1.5 billion to $1.5 billion does not indicate a material increase in scale.
Liabilities grew faster than assets: +167.6% versus +0.6%. A substantial part of expansion was externally funded.
Equity was negative at the end of the period. Liabilities exceeded assets, leaving no balance sheet cushion.
The period ended with net cash: net debt stood at -$385 million. This supports financial flexibility.
The cash share moved from 20.2% to 27.5%. A higher figure generally provides more room in an adverse scenario.
Retained earnings are negative at -$4.5 billion. This reduces the formal capital cushion, although large shareholder returns may have contributed.
Balance sheet takeaway
Ultragenyx Pharmaceutical 's balance sheet profile remains vulnerable. Lower liabilities and capital accumulation are the main routes to improvement.
Annual Balance Sheet Ultragenyx Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-385 M | -134 M | -171 M | - | -297 M | - | - | - | - | -161 M | -93.6 M | -24.3 M | -7.43 M | -86.2 M | -10.6 M |
Long Term Debt |
24 M | 30 M | 30.6 M | - | 410 K | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
12 M | 10 M | 12.6 M | - | 10.5 M | - | 7.24 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
1.22 B | 897 M | 935 M | 932 M | 418 M | 416 M | 378 M | 35.9 M | 36.3 M | 6.39 M | 561 K | 505 K | 3.62 M | 788 K | 487 K |
Total Current Liabilities |
384 M | 344 M | 280 M | 261 M | 181 M | 190 M | 103 M | 74.7 M | 71 M | 60.3 M | 27.9 M | 12.5 M | - | - | - |
Total Liabilities |
1.6 B | 1.24 B | 1.22 B | 1.19 B | 600 M | 605 M | 482 M | 111 M | 107 M | 66.7 M | 28.5 M | 13 M | 9.54 M | 3.98 M | 1.49 M |
Deferred Revenue |
- | - | - | - | 9.08 M | 59.2 M | - | - | 5.99 M | - | - | - | - | - | - |
Retained Earnings |
-4.53 B | -3.96 B | -3.39 B | -2.78 B | -2.07 B | -1.62 B | -1.43 B | -1.03 B | -833 M | -531 M | -285 M | -139 M | -74.8 M | -27.1 M | -8.16 M |
Total Assets |
1.53 B | 1.5 B | 1.49 B | 1.55 B | 1.52 B | 1.76 B | 1.14 B | 720 M | 491 M | 541 M | 560 M | 198 M | 59.6 M | 88.3 M | 12.1 M |
Cash and Cash Equivalents |
421 M | 174 M | 214 M | 133 M | 308 M | 714 M | 434 M | 113 M | 100 M | 161 M | 93.6 M | 24.3 M | 7.43 M | 86.2 M | - |
Book Value |
-73 M | 262 M | 275 M | 352 M | 923 M | 1.15 B | 654 M | 609 M | 383 M | 474 M | 531 M | 185 M | 50.1 M | 84.3 M | 10.6 M |
Total Shareholders Equity |
-80 M | 255 M | 275 M | 352 M | 923 M | 1.15 B | 654 M | 609 M | 383 M | 474 M | 531 M | 185 M | -74.8 M | -27 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Ultragenyx Pharmaceutical
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | 24 M | 21.7 M | 24.5 M | 27.8 M | 30 M | - | - | - | 30.6 M | - | - | - | 19.8 M | - | - | - | 30.5 M | - | - | - | 38.6 M | 36.7 M | 36.3 M | 35 M | 29.8 M | 31.2 M | 33 M | 23 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
1.17 B | 1.2 B | 1.2 B | 1.22 B | 834 M | 855 M | 869 M | 897 M | 900 M | 913 M | 921 M | 935 M | 952 M | 938 M | 945 M | 932 M | 922 M | 422 M | 420 M | 418 M | 415 M | 413 M | 416 M | 416 M | 401 M | 399 M | 427 M | 378 M | 62.4 M | 64.1 M | 54.2 M | 35.9 M | 35.9 M | 36 M | 36.1 M | 36.3 M | 5.23 M | 5.41 M | 5.59 M | 6.39 M | 8.84 M | 6.07 M | 4.48 M | 561 K | 634 K | 684 K | 478 K | 505 K | 533 K | 560 K | 182 K | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
1.56 B | 1.55 B | 1.52 B | 1.6 B | 1.17 B | 1.15 B | 1.16 B | 1.24 B | 1.18 B | 1.19 B | 1.17 B | 1.22 B | 1.21 B | 1.18 B | 1.16 B | 1.19 B | 1.15 B | 643 M | 588 M | 600 M | 551 M | 540 M | 543 M | 605 M | 602 M | 618 M | 624 M | 482 M | 153 M | 139 M | 121 M | 111 M | 103 M | 102 M | 93.7 M | 107 M | 69.5 M | 68.1 M | 57.3 M | 66.7 M | 59.3 M | 38.1 M | 34.4 M | 28.5 M | 25.4 M | 23.7 M | 14.7 M | 13 M | 11.6 M | 9.5 M | 6.99 M | 9.54 M | 9.54 M | 9.54 M | 9.54 M | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 4.44 M | 5.87 M | 9.08 M | - | 3.91 M | 25.1 M | 66.6 M | 103 M | 135 M | 145 M | - | 16 K | 55 K | 69 K | - | - | 1.24 M | - | 5.99 M | 5.99 M | 5.99 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-4.93 B | -4.81 B | -4.72 B | -4.53 B | -4.4 B | -4.22 B | -4.11 B | -3.96 B | -3.82 B | -3.69 B | -3.56 B | -3.39 B | -3.26 B | -3.1 B | -2.94 B | -2.78 B | -2.63 B | -2.38 B | -2.23 B | -2.07 B | -1.95 B | -1.88 B | -1.76 B | -1.62 B | -1.6 B | -1.53 B | -1.55 B | -1.43 B | -1.34 B | -1.23 B | -1.13 B | -1.03 B | -942 M | -855 M | -802 M | -833 M | -751 M | -672 M | -599 M | -531 M | -459 M | -394 M | -337 M | -285 M | -229 M | -190 M | -160 M | -139 M | -122 M | -106 M | -92.9 M | -74.8 M | -74.8 M | -74.8 M | -74.8 M | - | - | - | - | - | - | - | - |
Total Assets |
1.19 B | 1.26 B | 1.3 B | 1.53 B | 1.19 B | 1.31 B | 1.31 B | 1.5 B | 1.54 B | 1.62 B | 1.31 B | 1.49 B | 1.24 B | 1.31 B | 1.38 B | 1.55 B | 1.62 B | 1.32 B | 1.38 B | 1.52 B | 1.48 B | 1.51 B | 1.6 B | 1.76 B | 1.27 B | 1.31 B | 1.23 B | 1.14 B | 880 M | 959 M | 1.01 B | 720 M | 765 M | 806 M | 817 M | 491 M | 435 M | 498 M | 546 M | 541 M | 515 M | 482 M | 524 M | 560 M | 602 M | 343 M | 356 M | 198 M | 211 M | 163 M | 173 M | 59.6 M | 59.6 M | 59.6 M | 59.6 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
150 M | 125 M | 175 M | 421 M | 203 M | 176 M | 127 M | 174 M | 151 M | 481 M | 112 M | 214 M | 72.6 M | 102 M | 85.8 M | 133 M | 392 M | 160 M | 154 M | 308 M | 198 M | 291 M | 384 M | 714 M | 197 M | 336 M | 298 M | 434 M | 123 M | 131 M | 270 M | 113 M | 83 M | 113 M | 229 M | 103 M | 60.4 M | 93 M | 162 M | 165 M | 142 M | 55.1 M | 70.8 M | 93.6 M | 167 M | 52.4 M | 178 M | 24.3 M | 53.4 M | 17.5 M | 55.4 M | 7.43 M | 7.43 M | 7.43 M | 7.43 M | 86.2 M | - | - | - | 10.6 M | - | - | - |
Book Value |
-369 M | -284 M | -229 M | -73 M | 16.2 M | 158 M | 151 M | 262 M | 354 M | 432 M | 140 M | 275 M | 31.7 M | 129 M | 220 M | 352 M | 469 M | 678 M | 796 M | 923 M | 934 M | 972 M | 1.05 B | 1.15 B | 666 M | 696 M | 609 M | 654 M | 727 M | 820 M | 887 M | 609 M | 663 M | 704 M | 724 M | 383 M | 366 M | 429 M | 488 M | 474 M | 456 M | 444 M | 490 M | 531 M | 577 M | 319 M | 341 M | 185 M | 199 M | 153 M | 166 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
-376 M | -291 M | -236 M | -80 M | 10 M | 151 M | 144 M | 255 M | 347 M | 432 M | 140 M | 275 M | 31.7 M | 129 M | 220 M | 352 M | 469 M | 678 M | 796 M | 923 M | 934 M | 972 M | 1.05 B | 1.15 B | 666 M | 696 M | 609 M | 654 M | 727 M | 820 M | 887 M | 609 M | 663 M | 704 M | 724 M | 383 M | 366 M | 429 M | 488 M | 474 M | 456 M | 444 M | 490 M | 531 M | 577 M | 319 M | 341 M | 185 M | 199 M | 153 M | 166 M | -74.8 M | -74.8 M | -74.8 M | -74.8 M | -27 M | - | - | - | -7.96 M | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Ultragenyx Pharmaceutical , providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Russia
USA
Canada
Niderland
Israel
Schweiz
Australia
Britain
